Phase 2 Study of Venetoclax Plus Rituximab or Randomized Ven Plus Bendamustine plus Rituximab (BR) Versus BR in Patients with Relapsed/Refractory Follicular Lymphoma: Interim Data

被引：8
|
作者：
Zinzani, Pier Luigi [1 ]
Topp, Max S. [2 ]
Yuen, Sam L. S. [3 ]
Rusconi, Chiara [4 ]
Fleury, Isabelle [5 ,6 ]
Pro, Barbara [7 ]
Gritti, Giuseppe [8 ]
Crump, Michael [9 ]
Hsu, Wanling [10 ]
Punnoose, Elizabeth A. [10 ]
Hilger, James [10 ]
Mobasher, Mehrdad [10 ]
Hiddermann, Wolfgang [11 ]
机构：
[1] Univ Bologna, Inst Hematol LEA Seragnoli, Bologna, Italy
[2] Univ Wurzburg, Med Klin & Poliklin 2, Wurzburg, Germany
[3] Calvary Mater Newcastle, Dept Haematol, Newcastle, NSW, Australia
[4] Osped Niguarda Ca Granda, Div Hematol, Milan, Italy
[5] Maisonneuve Rosemont Hosp, Dept Hematol, Montreal, PQ, Canada
[6] Univ Montreal, Montreal, PQ, Canada
[7] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL USA
[8] Osped Papa Giovanni XXIII, Hematol & BMT Unit, Bergamo, Italy
[9] Princess Margaret Canc Ctr, Div Med Oncol & Hematol, Toronto, ON, Canada
[10] Genentech Inc, San Francisco, CA USA
[11] Klinikum Univ Munchen, Dept Internal Med 3, Munich, Germany
来源：
BLOOD | 2016年 / 128卷 / 22期
关键词：
D O I：
10.1182/blood.V128.22.617.617
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
617
引用
收藏
页数：7
相关论文
共 50 条
  • [31] inMIND: A Phase 3 Study of Tafasitamab Plus Lenalidomide and Rituximab Versus Placebo Plus Lenalidomide and Rituximab for Relapsed/Refractory (R/R) Follicular Lymphoma (FL) or Marginal Zone Lymphoma (MZL)
    Sehn, Laurie H.
    Hubel, Kai
    Luminari, Stefano
    Salar, Antonio
    Wahlin, Bjorn E.
    Gopal, Ajay K.
    Bonnet, Christophe
    Paneesha, Shankara
    Trneny, Marek
    Mashegu, Hafsat
    Lihou, Christine F.
    Cheng, Lulu
    Scholz, Christian W.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S385 - S386
  • [32] RELEVANCE: Phase III randomized study of lenalidomide plus rituximab (R2) versus chemotherapy plus rituximab, followed by rituximab maintenance, in patients with previously untreated follicular lymphoma.
    Fowler, Nathan Hale
    Morschhauser, Franck
    Feugier, Pierre
    Bouabdallah, Reda
    Tilly, Herve
    Palomba, Maria Lia
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [33] A Phase III study of zanubrutinib plus rituximab versus bendamustine plus rituximab in transplant-ineligible, untreated mantle cell lymphoma
    Dreyling, Martin
    Tam, Constantine S.
    Wang, Michael
    Smith, Stephen D.
    Ladetto, Marco
    Huang, Huiqiang
    Novotny, William
    Co, Melannie
    Romano, Alfredo
    Holmgren, Eric
    Huang, Jane
    Le Gouill, Steven
    FUTURE ONCOLOGY, 2021, 17 (03) : 255 - 262
  • [34] A Phase III, Randomized, Double-Blind, Study of Tazemetostat or Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory Follicular Lymphoma
    Salles, Gilles
    Shah, Harsh
    Leonard, John P.
    Szanto, Attila
    Chen, Jade
    Bannerji, Rajat
    Morschhauser, Franck
    Nastoupil, Loretta J.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S454 - S455
  • [35] BENDAMUSTINE PLUS RITUXIMAB IN PATIENTS WITH RELAPSED OR REFRACTORY WALDENSTROM'S MACROGLOBULINEMIA (WM)
    Improta, S.
    Villa, M.
    Gagliardi, A.
    Lucania, A.
    Della Cioppa, P.
    Esposito, M.
    Mastrullo, L.
    HAEMATOLOGICA, 2013, 98 : 638 - 638
  • [36] Acalabrutinib (Acala) vs Idelalisib plus Rituximab (IdR) or Bendamustine plus Rituximab (BR) in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): ASCEND final results
    Welslau, M.
    Ghia, P.
    Pluta, A.
    Wach, M.
    Lysak, D.
    Kozak, T.
    Simkovic, M.
    Kaplan, P.
    Kraychok, I
    Illes, A.
    de la Serna, J.
    Dolan, S.
    Campbell, P.
    Musuraca, G.
    Jacob, A.
    Avery, E. J.
    Lee, J. H.
    Wang, D.
    Patel, P.
    Quah, C.
    Jurczak, W.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 71 - 72
  • [37] Acalabrutinib (Acala) vs Idelalisib plus Rituximab (IdR) or Bendamustine plus Rituximab (BR) in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): ASCEND Final Results
    Jacob, Abraham
    Ghia, Paolo
    Pluta, Andrzej
    Wach, Malgorzata
    Lysak, Daniel
    Kozak, Tomas
    Simkovic, Martin
    Kaplan, Polina
    Kraychok, Iryna
    Illes, Arpad
    De La Serna, Javier
    Dolan, Sean
    Campbell, Philip
    Musuraca, Gerardo
    Avery, Eric Joseph
    Lee, Jae Hoon
    Wang, Denise
    Patel, Priti
    Quah, Cheng Seok
    Jurczak, Wojciech
    BRITISH JOURNAL OF HAEMATOLOGY, 2021, 193 : 141 - 142
  • [38] Idelalisib Plus Bendamustine and Rituximab (BR) Is Superior to BR Alone in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Results of a Phase 3 Randomized Double-Blind Placebo-Controlled Study
    Zelenetz, Andrew D.
    Robak, Tadeusz
    Coiffier, Bertrand
    Delgado, Julio
    Marlton, Paula
    Adewoye, Adeboye H.
    Kim, Yeonhee
    Dreiling, Lyndah K.
    Hillmen, Peter
    BLOOD, 2015, 126 (23)
  • [39] Idelalisib plus bendamustine and rituximab (BR) is superior to BR alone in patients with relapsed/refractory chronic lymphocytic leukemia: Results of a phase 3 randomized double-blind placebo-controlled study
    Zelenetz, A.
    Robak, T.
    Coiffier, B.
    Delgado, J.
    Marlton, P.
    Adewoye, A.
    Kim, Y.
    Dreiling, L.
    Hillmen, P.
    BRITISH JOURNAL OF HAEMATOLOGY, 2016, 173 : 10 - 10
  • [40] Obinutuzumab plus bendamustine in rituximab-refractory indolent lymphoma
    Hamlin, Paul A.
    LANCET ONCOLOGY, 2016, 17 (08): : 1023 - 1025
12345